General form of registration statement for all companies including face-amount certificate companies

Condensed Consolidated Balance Sheets (Current Period Unaudited)

v3.24.4
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2024
Jun. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Current assets:              
Cash and cash equivalents $ 14,207   $ 7,350     $ 16,053  
Prepaid expenses and other current assets 441   198     471  
Total current assets 16,321   7,548     16,524  
Current liabilities:              
Accounts payable 3,130   936     3,181  
Accrued expenses and other current liabilities 4,505   1,424     2,601  
Total current liabilities 7,635   2,360     5,782  
Stockholders’ equity:              
Common stock 0   0     0  
Additional paid-in capital 2,380   1,818     1,215  
Accumulated deficit (89,784)   (76,301)     (94,992)  
Total stockholders’ equity (87,404) $ (80,828) (74,483) $ (95,171) $ (92,493) (93,777) $ (66,686)
Total liabilities and stockholders’ equity 16,321   7,548     16,524  
Pieris Pharmaceuticals, Inc. [Member]              
Current assets:              
Cash and cash equivalents 19,363   17,396     38,635  
Short term investments 0   8,970     20,534  
Accounts receivable 373   572     5,810  
Receivable from public grants 0   3,141     4,771  
Other receivables 506   2,326     462  
Assets held for sale, property and equipment 0   2,188     0  
Prepaid expenses and other current assets 280   4,087     3,212  
Total current assets 20,522   38,680     95,490  
Current liabilities:              
Accounts payable 801   3,372     4,154  
Accrued expenses and other current liabilities 3,453   8,550     10,746  
Total current liabilities 4,254   11,922     36,583  
Stockholders’ equity:              
Preferred stock 0   0     0  
Common stock 1   1     1  
Additional paid-in capital 342,916   341,693     318,603  
Accumulated other comprehensive income (loss) (316)   28     (254)  
Accumulated deficit (326,333)   (314,964)     (290,421)  
Total stockholders’ equity 16,268 $ 18,705 26,758 $ 30,510 $ 40,498 27,929 $ 50,755
Total liabilities and stockholders’ equity $ 20,522   $ 38,680     $ 95,490